脂质体阿霉素治疗乳腺癌患者的综述
Liposomal Doxorubicin in the treatment of breast cancer patients: a review.
作者信息
Lao Juan, Madani Julia, Puértolas Teresa, Alvarez María, Hernández Alba, Pazo-Cid Roberto, Artal Angel, Antón Torres Antonio
机构信息
Medical Oncology Department, Miguel Servet University Hospital, Paseo Isabel la Católica, 1-3, 50009 Zaragoza, Spain ; Aragón Institute of Health Sciences, Avda. San Juan Bosco, 13, planta 1, 50009 Zaragoza, Spain.
出版信息
J Drug Deliv. 2013;2013:456409. doi: 10.1155/2013/456409. Epub 2013 Mar 26.
Abstract
Drug delivery systems can provide enhanced efficacy and/or reduced toxicity for anticancer agents. Liposome drug delivery systems are able to modify the pharmacokinetics and biodistribution of cytostatic agents, increasing the concentration of the drug released to neoplastic tissue and reducing the exposure of normal tissue. Anthracyclines are a key drug in the treatment of both metastatic and early breast cancer, but one of their major limitations is cardiotoxicity. One of the strategies designed to minimize this side effect is liposome encapsulation. Liposomal anthracyclines have achieved highly efficient drug encapsulation and they have proven to be effective and with reduced cardiotoxicity, as a single agent or in combination with other drugs for the treatment of either anthracyclines-treated or naïve metastatic breast cancer patients. Of particular interest is the use of the combination of liposomal anthracyclines and trastuzumab in patients with HER2-overexpressing breast cancer. In this paper, we discuss the different studies on liposomal doxorubicin in metastatic and early breast cancer therapy.
摘要
药物递送系统能够提高抗癌药物的疗效和/或降低其毒性。脂质体药物递送系统能够改变细胞抑制剂的药代动力学和生物分布，增加释放到肿瘤组织中的药物浓度，并减少正常组织的暴露。蒽环类药物是治疗转移性和早期乳腺癌的关键药物，但其主要局限性之一是心脏毒性。旨在将这种副作用降至最低的策略之一是脂质体包封。脂质体蒽环类药物已实现高效的药物包封，并且已证明作为单一药物或与其他药物联合用于治疗接受过蒽环类药物治疗或未接受过治疗的转移性乳腺癌患者时，它们有效且心脏毒性降低。特别值得关注的是脂质体蒽环类药物与曲妥珠单抗联合用于HER2过表达乳腺癌患者的情况。在本文中，我们讨论了关于脂质体阿霉素在转移性和早期乳腺癌治疗中的不同研究。
相似文献
1
Liposomal Doxorubicin in the treatment of breast cancer patients: a review.脂质体阿霉素治疗乳腺癌患者的综述
J Drug Deliv. 2013;2013:456409. doi: 10.1155/2013/456409. Epub 2013 Mar 26.
2
HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician's choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancer.赫敏：一项随机2期试验，比较MM - 302联合曲妥珠单抗与医生选择的化疗方案联合曲妥珠单抗，用于治疗既往接受过治疗、未使用过蒽环类药物、HER2阳性、局部晚期/转移性乳腺癌患者。
BMC Cancer. 2016 Jun 3;16:352. doi: 10.1186/s12885-016-2385-z.
3
Liposomal anthracyclines in metastatic breast cancer: clinical update.脂质体蒽环类药物在转移性乳腺癌中的应用：临床进展
Oncologist. 2003;8 Suppl 2:3-9. doi: 10.1634/theoncologist.8-suppl_2-3.
4
HER2-targeted liposomal doxorubicin displays enhanced anti-tumorigenic effects without associated cardiotoxicity.曲妥珠单抗靶向脂质体多柔比星显示出增强的抗肿瘤作用而无相关心脏毒性。
Toxicol Appl Pharmacol. 2012 Jul 1;262(1):1-10. doi: 10.1016/j.taap.2012.04.008. Epub 2012 Apr 21.
5
Liposome-based drug delivery in breast cancer treatment.基于脂质体的药物递送在乳腺癌治疗中的应用。
Breast Cancer Res. 2002;4(3):95-9. doi: 10.1186/bcr432. Epub 2002 Apr 18.
6
Metastatic breast cancer: the role of pegylated liposomal doxorubicin after conventional anthracyclines.转移性乳腺癌：传统蒽环类药物治疗后聚乙二醇化脂质体阿霉素的作用
Cancer Treat Rev. 2008 Aug;34(5):391-406. doi: 10.1016/j.ctrv.2008.01.008. Epub 2008 Mar 20.
7
Trastuzumab, non-pegylated liposomal-encapsulated doxorubicin and paclitaxel in the neoadjuvant setting of HER-2 positive breast cancer.曲妥珠单抗、非聚乙二醇化脂质体包裹的阿霉素和紫杉醇用于HER-2阳性乳腺癌的新辅助治疗。
Int J Clin Pharm. 2016 Apr;38(2):446-53. doi: 10.1007/s11096-016-0278-5. Epub 2016 Mar 7.
8
Anthracycline-trastuzumab regimens for HER2/neu-overexpressing breast cancer: current experience and future strategies.用于HER2/neu过表达乳腺癌的蒽环类-曲妥珠单抗治疗方案：当前经验与未来策略。
Ann Oncol. 2008 Sep;19(9):1530-9. doi: 10.1093/annonc/mdn292. Epub 2008 May 13.
9
Role of liposomal anthracyclines in breast cancer.脂质体蒽环类药物在乳腺癌中的作用。
Ann Oncol. 2007 Jun;18 Suppl 6:vi70-3. doi: 10.1093/annonc/mdm229.
10
New approaches in the management of advanced breast cancer - role of combination treatment with liposomal doxorubicin.晚期乳腺癌治疗新方法——脂质体多柔比星联合治疗的作用。
Breast Cancer (Dove Med Press). 2009 Aug 31;1:1-18.
引用本文的文献
1
Therapeutic peptides and their delivery using lipid-based nanoparticles.治疗性肽及其基于脂质的纳米颗粒递送
Tzu Chi Med J. 2025 May 2;37(3):223-234. doi: 10.4103/tcmj.tcmj_321_24. eCollection 2025 Jul-Sep.
2
NSAID-encapsulated nanoparticles as a targeted therapeutic platform for modulating chronic inflammation and inhibiting cancer progression: a review.非甾体抗炎药包裹的纳米颗粒作为调节慢性炎症和抑制癌症进展的靶向治疗平台：综述
Inflammopharmacology. 2025 Apr 26. doi: 10.1007/s10787-025-01760-8.
3
The Fomivirsen, Patisiran, and Givosiran Odyssey: How the Success Stories May Pave the Way for Future Clinical Translation of Nucleic Acid Drugs.福米韦生、帕替拉韦和吉沃赛生的历程：成功案例如何为核酸药物未来的临床转化铺平道路。
BioDrugs. 2025 May;39(3):359-371. doi: 10.1007/s40259-025-00711-7. Epub 2025 Apr 5.
4
Doxorubicin-loaded pH-responsive porphyrin-derived carbon dots as a promising biocompatible drug delivery system for effective chemotherapy of breast cancer.负载阿霉素的pH响应性卟啉衍生碳点作为一种有前景的生物相容性药物递送系统用于乳腺癌的有效化疗
RSC Adv. 2025 Feb 26;15(9):6457-6473. doi: 10.1039/d4ra09058f.
5
MiRNAs function in the development of resistance against doxorubicin in cancer cells: targeting ABC transporters.微小RNA在癌细胞对多柔比星耐药性发展中的作用：靶向ATP结合盒转运蛋白
Front Pharmacol. 2024 Nov 29;15:1486783. doi: 10.3389/fphar.2024.1486783. eCollection 2024.
6
Envisioning Clinical Management of Breast Cancer: a Comprehensive Review.展望乳腺癌的临床管理：一项综合综述。
Curr Drug Discov Technol. 2025;22(2):e290424229495. doi: 10.2174/0115701638300812240417055802.
7
Targeting of focal adhesion kinase enhances the immunogenic cell death of PEGylated liposome doxorubicin to optimize therapeutic responses of immune checkpoint blockade.靶向粘着斑激酶可增强聚乙二醇化脂质体阿霉素的免疫原性细胞死亡，以优化免疫检查点阻断的治疗反应。
J Exp Clin Cancer Res. 2024 Feb 19;43(1):51. doi: 10.1186/s13046-024-02974-4.
8
In Vitro and Preclinical Antitumor Evaluation of Doxorubicin Liposomes Coated with a Cholesterol-Based Trimeric β-D-Glucopyranosyltriazole.基于胆固醇的三聚体β-D-吡喃葡萄糖基三唑包被的阿霉素脂质体的体外及临床前抗肿瘤评价
Pharmaceutics. 2023 Dec 11;15(12):2751. doi: 10.3390/pharmaceutics15122751.
9
An Automated Electroanalytical Method for the Drug Release Profiling of Liposomal Doxorubicin HCl Formulations.一种用于盐酸多柔比星脂质体制剂药物释放特征分析的自动化电化学方法。
J Pharm Sci. 2024 Mar;113(3):791-797. doi: 10.1016/j.xphs.2023.11.035. Epub 2023 Dec 9.
10
Drug repositioning based on weighted local information augmented graph neural network.基于加权局部信息增强图神经网络的药物重定位。
Brief Bioinform. 2023 Nov 22;25(1). doi: 10.1093/bib/bbad431.
本文引用的文献
1
The treatment of breast cancer using liposome technology.利用脂质体技术治疗乳腺癌。
J Drug Deliv. 2012;2012:212965. doi: 10.1155/2012/212965. Epub 2012 Feb 21.
2
Cardiac safety of adjuvant pegylated liposomal doxorubicin with concurrent trastuzumab: a randomized phase II trial.辅助性聚乙二醇脂质体阿霉素联合曲妥珠单抗的心脏安全性：一项随机 II 期试验。
Ann Oncol. 2012 Jul;23(7):1780-8. doi: 10.1093/annonc/mdr519. Epub 2011 Nov 4.
3
Adjuvant trastuzumab in HER2-positive breast cancer.曲妥珠单抗辅助治疗 HER2 阳性乳腺癌。
N Engl J Med. 2011 Oct 6;365(14):1273-83. doi: 10.1056/NEJMoa0910383.
4
Myotax: a phase II trial of docetaxel plus non-pegylated liposomal doxorubicin as first-line therapy of metastatic breast cancer previously treated with adjuvant anthracyclines.美托泰昔：多西他赛联合非聚乙二醇脂质体阿霉素作为蒽环类辅助化疗后转移性乳腺癌一线治疗的 II 期临床研究
Eur J Cancer. 2011 Nov;47(16):2396-402. doi: 10.1016/j.ejca.2011.08.004. Epub 2011 Sep 13.
5
Single-agent pegylated liposomal doxorubicin (PLD) in the treatment of metastatic breast cancer: results of an Austrian observational trial.单药聚乙二醇脂质体阿霉素（PLD）治疗转移性乳腺癌：一项奥地利观察性试验的结果。
BMC Cancer. 2011 Aug 24;11:373. doi: 10.1186/1471-2407-11-373.
6
A phase I/II trial of non-pegylated liposomal doxorubicin, docetaxel and trastuzumab as first-line treatment in HER-2-positive locally advanced or metastatic breast cancer.一项非聚乙二醇化脂质体多柔比星、多西他赛和曲妥珠单抗作为一线治疗 HER-2 阳性局部晚期或转移性乳腺癌的 I/II 期临床试验。
Eur J Cancer. 2011 Sep;47(14):2091-8. doi: 10.1016/j.ejca.2011.05.005. Epub 2011 Jun 12.
7
Pegylated liposomal doxorubicin in combination with cyclophosphamide and trastuzumab in HER2-positive metastatic breast cancer patients: efficacy and cardiac safety from the GEICAM/2004-05 study.聚乙二醇脂质体阿霉素联合环磷酰胺和曲妥珠单抗治疗人表皮生长因子受体 2 阳性转移性乳腺癌患者：来自 GEICAM/2004-05 研究的疗效和心脏安全性。
Ann Oncol. 2011 Dec;22(12):2591-2596. doi: 10.1093/annonc/mdr024. Epub 2011 Mar 17.
8
Transient over-expression of estrogen receptor-α in breast cancer cells promotes cell survival and estrogen-independent growth.乳腺癌细胞中雌激素受体-α的瞬时过表达促进细胞存活和雌激素非依赖性生长。
Breast Cancer Res Treat. 2011 Jul;128(2):357-68. doi: 10.1007/s10549-010-1122-6. Epub 2010 Aug 22.
9
Weekly combination of non-pegylated liposomal doxorubicin and taxane in first-line breast cancer: wALT trial (phase I-II).一线乳腺癌中每周联合应用非聚乙二醇化脂质体阿霉素和紫杉烷类药物：wALT 试验（I-II 期）。
Ann Oncol. 2011 Feb;22(2):315-20. doi: 10.1093/annonc/mdq392. Epub 2010 Aug 6.
10
Phase II clinical trial of liposomal-encapsulated doxorubicin citrate and docetaxel, associated with trastuzumab, as neoadjuvant treatment in stages II and IIIA HER2-overexpressing breast cancer patients. GEICAM 2003-03 study.多柔比星脂质体柠檬酸酯和多西他赛联合曲妥珠单抗作为新辅助治疗在 HER2 过表达的 II 期和 IIIA 期乳腺癌患者中的 II 期临床试验。GEICAM 2003-03 研究。
Ann Oncol. 2011 Jan;22(1):74-79. doi: 10.1093/annonc/mdq317. Epub 2010 Jul 5.
Zotero 插件